(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600276 · · 11 pages · Chinese
Summary by 6ix AI
The report highlights significant increases in revenue and net profit compared to the same period last year, driven by growth in innovative drug sales and licensing income. The company also reported a decline in revenue from generic drugs due to ongoing market pressures and policy impacts. Additionally, the report outlines advancements in research and development, including new drug approvals and collaborations with international partners.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Earlier from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance by the EMA of the Application for Drug Marketing Authorization
- Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer
- Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
Later from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion in the Priority Review Program
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 6th Meeting of the 10th Board of Directors
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on FDA Acceptance of the Resubmitted Biologics License Application for Camrelizumab for Injection
- Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Satisfaction of Unlocking Conditions for Certain Shares under the 2025 A-Share Employee Stock Ownership Plan and Expiration of the 1st Lock-up Period
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals